任春霞 趙敏 徐娜 宋亞琴 陳亞萍 呂蓓 楊恭
1江蘇省無錫市人民醫(yī)院婦產(chǎn)科,江蘇 無錫 214023;2山東省交通醫(yī)院婦產(chǎn)科,山東 濟南 250031;3復旦大學附屬上海市第五人民醫(yī)院婦產(chǎn)科,復旦大學上海醫(yī)學院婦產(chǎn)科學系,上海 200240;4復旦大學附屬上海市第五人民醫(yī)院中心實驗室,復旦大學上海醫(yī)學院婦產(chǎn)科學系,上海 200240 5復旦大學附屬腫瘤醫(yī)院腫瘤研究所,復旦大學上海醫(yī)學院腫瘤學系,上海 200032
癌相關(guān)成纖維細胞通過IL-6誘導的“上皮-間質(zhì)”轉(zhuǎn)換促進宮頸癌細胞的遷移和侵襲
任春霞1 趙敏2 徐娜1 宋亞琴1 陳亞萍3 呂蓓1 楊恭4,5
1江蘇省無錫市人民醫(yī)院婦產(chǎn)科,江蘇 無錫 214023;2山東省交通醫(yī)院婦產(chǎn)科,山東 濟南 250031;3復旦大學附屬上海市第五人民醫(yī)院婦產(chǎn)科,復旦大學上海醫(yī)學院婦產(chǎn)科學系,上海 200240;4復旦大學附屬上海市第五人民醫(yī)院中心實驗室,復旦大學上海醫(yī)學院婦產(chǎn)科學系,上海 200240 5復旦大學附屬腫瘤醫(yī)院腫瘤研究所,復旦大學上海醫(yī)學院腫瘤學系,上海 200032
背景與目的:癌相關(guān)成纖維細胞(cancer-associated fibroblasts,CAFs)能促進上皮腫瘤的侵襲和轉(zhuǎn)移,細胞因子IL-6在腫瘤間質(zhì)微環(huán)境中可能介導間質(zhì)和上皮的相互作用,促進腫瘤的侵襲和轉(zhuǎn)移,但其具體機制尚不十分清楚。方法:以宮頸癌細胞HeLa為研究模型,用ELISA測定宮頸癌CAFs和正常宮頸組織成纖維細胞(normal fibroblasts,NFs)條件培養(yǎng)基中IL-6的表達;用條件培養(yǎng)基或IL-6分別處理宮頸癌細胞系HeLa;用Western blot測定樣品處理前后上皮-間質(zhì)轉(zhuǎn)化(epithelial-mesenchymal transition,EMT)標志物(如N-Cadherin和Vimentin等)的變化,同時用劃痕和transwell小室測定細胞遷移和侵襲能力的變化。結(jié)果:CAF中IL-6表達比NF高4~5倍;與對照組相比,用CAF條件培養(yǎng)基或IL-6處理的HeLa細胞間充質(zhì)細胞標志物Vimentin和N-Cadherin升高,而上皮細胞標志物E-Cadherin和Cytokeratin下降,表明IL-6可以促進細胞的EMT發(fā)生;進一步研究發(fā)現(xiàn)過量IL-6處理的HeLa細胞中干細胞轉(zhuǎn)錄因子Snail 1隨STAT3的激活而上升;同時發(fā)現(xiàn)過量IL-6處理的HeLa細胞的遷移和侵襲能力大幅增加。結(jié)論:CAF在腫瘤微環(huán)境中可能通過IL-6/STAT3/Snail通路誘導宮頸癌上皮細胞的EMT轉(zhuǎn)化,從而促進宮頸癌的侵襲和轉(zhuǎn)移能力。
癌相關(guān)成纖維細胞;宮頸癌;白介素6;上皮-間質(zhì)轉(zhuǎn)換;遷移和侵襲
近年來,間質(zhì)微環(huán)境對腫瘤發(fā)生、發(fā)展的作用機制是腫瘤研究的熱點,其中癌相關(guān)成纖維細胞(cancer-associated fi broblasts,CAFs)的特性對上皮類腫瘤的發(fā)生尤為重要,因此,CAFs調(diào)節(jié)腫瘤發(fā)生、發(fā)展的機制得到廣泛的研究。如CAFs作為腫瘤相關(guān)的炎性反應源,可能對腫瘤的發(fā)生和發(fā)展均有一定作用[1-2]。三陰性乳腺癌中CAFs以CXCL12和IGF1介導的PI3K-AKT信號通路對乳腺癌定向骨轉(zhuǎn)移具有決定性作用[3]。此外,CAFs可能通過其旁分泌的IL-33調(diào)節(jié)頭頸鱗癌細胞的侵襲能力[4]。
上皮-間質(zhì)轉(zhuǎn)換(epithelial-mesenchymal transition,EMT)是近年來腫瘤研究領域的另一熱點。EMT對腫瘤的轉(zhuǎn)移及其重要,如Pten丟失和PI3K/AKT激活可以誘導前列腺癌細胞發(fā)生EMT,進而促進前列腺癌的高轉(zhuǎn)移[5]。最近發(fā)現(xiàn),EMT可能是腫瘤干細胞的特征之一[6-7]。但與之相對的間質(zhì)-上皮轉(zhuǎn)換(mesenchymal-epithelial transition,MET)可能也與腫瘤轉(zhuǎn)移密切相關(guān)[8-9]。
有研究表明,CAFs可能在乳腺癌組織的邊緣通過基質(zhì)金屬蛋白酶促進乳腺癌細胞的EMT發(fā)生[10]。在舌鱗狀細胞癌中,CAFs可能通過Cadherin-11和FSP-1等分子調(diào)節(jié)EMT的發(fā)生和腫瘤轉(zhuǎn)移[11]。我們最近的研究發(fā)現(xiàn)細胞因子IL-6在CAFs中的表達比正常NFs高4~5倍[12],在宮頸癌微環(huán)境中,CAFs是否可以通過IL-6誘導EMT發(fā)生而促進宮頸癌的轉(zhuǎn)移和侵襲,目前鮮見報道,本研究旨在利用體外細胞學實驗驗證這一假說。
1.1 細胞系和培養(yǎng)基
宮頸癌細胞系HeLa來自美國模式菌種收集中心(ATCC),培養(yǎng)基為含10%胎牛血清、1 mmol/L非必需氨基酸、2 mmol /L L-谷氨酰胺、100 U/mL青霉素及100 μg/mL鏈霉素的DEME(購于美國Gibco公司),培養(yǎng)環(huán)境為37 ℃、CO2體積分數(shù)為5%的恒溫培養(yǎng)箱。
CAFs和NFs來自南京醫(yī)科大學附屬無錫市人民醫(yī)院婦產(chǎn)科2012年11月收治的患者4例。所有患者均為初治患者,術(shù)前均未接受任何治療。CAFs獲取源(宮頸癌IB1期行廣泛子宮切除術(shù)加盆腔淋巴結(jié)清掃術(shù)患者標本和宮頸癌IA1期行全子宮切除術(shù)患者標本2例);NFs獲取源為卵巢癌行全子宮加雙側(cè)附件切除術(shù)患者標本2例。標本獲取前均與患者簽署知情同意書,獲得本人許可。成纖維細胞分離方法見文獻[12]。成功分離到2株CAFs和2株NFs,體外培養(yǎng),增殖良好,實驗使用CAFs和NFs分別為體外第3代和第5代,無明顯衰老表型。
1.2 酶聯(lián)免疫吸附試驗(ELISA)
細胞培養(yǎng)基的收集見1.3,培養(yǎng)基中IL-6的測定按試劑盒(美國R&D System公司)操作說明。檢測步驟如下:
⑴用PBS稀釋一抗(IL-6Ab)至0.25 μg/mL ,迅速加入100 μL到每個孔中,室溫溫育過夜。
⑵吸出液體,每孔用300 μL wash buffer洗板4次。最后1次洗完后在紙上翻轉(zhuǎn)板,除去殘余的緩沖液。
⑶每孔中加300 μL的封閉液,在室溫下至少溫育1 h。洗板4次,方法同上。
⑷然后將IL-6標準品從1、0.75、0.5、0.25、0.125到0 ng/mL進行稀釋,加100 μL的標準品或者樣品到每個孔中,設三樣品孔重復,在室溫中至少溫育2 h。
⑸洗板4次,稀釋檢測抗體到1.0 μg/mL,每孔加100 μL。室溫溫育30 min。
⑹洗板4次,以1∶2 000稀釋Avidin-HRP第二抗體,每孔加100 μL,室溫溫育30 min。之后洗板4次,每孔加100 μL顯色劑,室溫下溫育,觀察顏色變化。
⑺最后,每孔加入終止液50 μL,用(650 nm波長)酶標儀讀取A值,求出IL-6相對濃度。
1.3 條件培養(yǎng)基或IL-6處理HeLa細胞
1.3.1 條件培養(yǎng)基(conditioned medium,CM)的收集
將HeLa細胞,CAFs或NFs在100 mm培養(yǎng)皿中進行正常單層培養(yǎng)至75%的密度,然后更換無血清培養(yǎng)基繼續(xù)培養(yǎng)48 h后收集培養(yǎng)基即為CM。PBS或無血清培養(yǎng)基作為對照。
1.3.2 細胞處理
將HeLa細胞在35 mm培養(yǎng)皿中正常培養(yǎng)至75%的密度,然后用含CAFs或NFs的CM,或200 ng/mL的IL-6(無血清)處理細胞48 h,收集24和48 h處理的細胞樣品,進行蛋白質(zhì)印跡法(Western blot)檢測或進行細胞遷移與侵襲檢測試驗。
1.4 Western blot檢測
主要用于E-cadherin、N-cadherin、cytokeratin、vimentin、pSTAT3(Tyr 705)和 Snail 1等蛋白的檢測,抗體均購自美國Cell Signaling Technology公司。將細胞用蛋白裂解緩沖液RIPA(25 mmol/L Tris-HCl,pH為7.6;150 mmol/L NaCl,1%NP-40,1%脫氧膽酸鈉-sodium deoxycholate,0.1% SDS)及適量蛋白酶抑制劑混合物(購自美國Sigma公司產(chǎn)品)裂解后,用BCA法測定蛋白濃度(試劑盒購自上海碧云天),然后用6×的SDS加樣緩沖液(125 mmol/L Tris-HCl,pH為6.8;2%SDS,20%甘油,0.2%溴酚藍)制備成適當濃度的樣品。樣品分離前,用100 ℃的水浴處理樣品3~5 min。然后用10%的SDS-聚丙烯酰胺凝膠電泳分離裂解的蛋白樣品。之后將蛋白轉(zhuǎn)移到聚偏二氟乙烯膜(PVDF membrane,購自美國Millpore公司)上,并用10%的脫脂奶粉(Bio-Rad)在室溫下封閉2 h。此后依次加入一抗和HRP(辣根氧化物酶)-偶聯(lián)的二抗(依一抗而定)。轉(zhuǎn)移的蛋白用化學發(fā)光底物(ECL,購自美國Millipore公司)進行顯色后,LAS4000化學發(fā)光成像分析儀曝光顯出條帶。
1.5 細胞劃痕實驗
分別將CM、IL-6、PBS或無血清培養(yǎng)基處理的HeLa細胞接種至6孔板中,每種細胞接種3個孔。等到細胞完全融合的時候,用10 μL槍頭在每孔單層細胞上劃痕,每孔劃出的“傷口”寬度要保持一致。PBS清洗一次,加無血清培養(yǎng)基,在37 ℃ ,CO2體積分數(shù)為5%的培養(yǎng)箱中培養(yǎng),0、12、24 h分別觀察劃痕愈合情況并拍照。計算不同時間段遷移的距離反應細胞遷移的能力,此實驗重復3次。
1.6 細胞侵襲實驗
用帶有8 μm微孔聚碳酸酯膜的transwell小室(購自美國BD公司)。首先將Matrigel(50 mg/L)膠和無血清DMEM培養(yǎng)基以1∶3比例進行混合。小室上室鋪100 μL混合好的Matrigel,37 ℃無菌保持過夜,確保Matrigel充分凝固。收集對數(shù)生長期的細胞,用無血清DMEM培養(yǎng)基調(diào)整細胞濃度為1×106mL-1,每孔加100 μL細胞懸液于上室,設3個重復孔,下室每孔加600 μL無血清DMEM。在37 ℃、體積分數(shù)為5%的CO2培養(yǎng)箱中溫育16 h后取出小室,濾膜用4%多聚甲醛固定20 min。用棉簽小心擦去未侵襲的濾膜表面細胞, 結(jié)晶紫染色,在光鏡下隨機選5個視野,計算細胞總數(shù),以穿過Matrigel的細胞數(shù)來表示腫瘤細胞的侵襲能力,本實驗重復3次。
2.1 IL-6分泌水平結(jié)果
本試驗測定了HeLa細胞,2株CAF細胞和2株NF細胞培養(yǎng)基中IL-6的水平,發(fā)現(xiàn)CAF培養(yǎng)基中IL-6>700 pg/mL,而NF培養(yǎng)基的IL-6濃度<150 pg/mL。此外,HeLa細胞中的IL-6濃度介于CAF和NF之間,為(365±28)pg/mL(圖1)。因此,在后續(xù)的實驗中我們主要使用CAF2的CM或IL-6(濃度為200 ng/mL),同時以NF的CM和PBS等作為對照處理細胞。
2.2 CAF條件培養(yǎng)基中IL-6促進HeLa細胞的EMT
用CAF的CM處理HeLa細胞24和48 h,分別測定了上皮細胞標志物E-Cadherin和Cytokeratin以及間充質(zhì)細胞標志物Vimentin和N-Cadherin的表達水平,發(fā)現(xiàn)E-Cadherin和Cytokeratin下降,而Vimentin和N-Cadherin上升(圖2A)。這些蛋白的變化標志著CAF的CM可能誘導宮頸癌細胞發(fā)生EMT。
圖1 用ELISA法測定的CAFs、NFs和HeLa細胞培養(yǎng)基中IL-6的相對濃度Fig. 1 Relative concentrations of IL-6 measured by ELISA in medium collected from cultures of CAFs, NFs and HeLa cells
為了測定CAF中CM促進EMT發(fā)生是否由于IL-6的作用,我們首先用IL-6處理了HeLa細胞,同時在CAF-CM或IL-6處理的HeLa細胞中,分別添加了IL-6中和抗體(購自美國R&D System公司),結(jié)果發(fā)現(xiàn)IL-6單獨處理的HeLa細胞也可以誘導HeLa細胞的EMT發(fā)生,而且IL-6中和抗體可以抑制EMT相關(guān)蛋白的表達(圖2B)。
圖2 用CAF2的條件培養(yǎng)基或IL-6處理的HeLa細胞48 h后顯示EMT相關(guān)分子的變化Fig. 2 Alterations of EMT-associated molecules in HeLa cells treated with CAF2 CM or IL-6 for 48 h.
2.3 STAT3激活是IL-6誘導EMT發(fā)生的關(guān)鍵
由于IL-6介導的主要細胞信號通路是受STAT3磷酸化控制的,而且EMT作為腫瘤干細胞的特征,轉(zhuǎn)錄因子Snail可能具有重要的調(diào)節(jié)功能。因此我們用Western blot檢測了STAT3的磷酸化和Snail 1的表達,同時在IL-6處理的細胞中加入STAT3抑制劑S31-201(美國Santa Cruz Biotechnology公司產(chǎn)品),進行了EMT 標志物的對比檢測。結(jié)果發(fā)現(xiàn)IL-6促進STAT3 Tyr705磷酸化和Snail 1表達的上升,抑制STAT3磷酸化,Snail 1的表達水平下降(圖3)。說明STAT3的磷酸化可能是IL-6誘導EMT發(fā)生的關(guān)鍵節(jié)點。
2.4 IL-6誘導的EMT促進宮頸癌細胞的遷移和侵襲
為了檢測IL-6誘導的EMT對HeLa細胞的生物學效應,我們用劃痕和transwell小室測定了細胞遷移和侵襲能力。結(jié)果表明,IL-6處理的HeLa細胞遷移能力和細胞的侵襲性均增強,而用IL-6抗體中和或用STAT3抑制劑再處理后,細胞的遷移和侵襲能力會下降(圖4)。
以上結(jié)果表明,腫瘤間質(zhì)微環(huán)境中CAFs可能通過其旁分泌的IL-6使宮頸癌上皮細胞STAT3激活和Snail 1上升,誘導EMT發(fā)生,從而促進宮頸癌的擴散和轉(zhuǎn)移。
圖3 IL-6激活STAT3磷酸化,以促進Snail 1的表達,β-actin為加樣對照Fig. 3 Activation of STAT3 by IL-6 promotes the expression of Snail 1,β-actin is a loading control
圖4 HeLa細胞用無血清培養(yǎng)基(SM)、IL-6、IL-6及其抗體(IL-6/Ab)、IL-6及STAT3抑制劑S30-201(IL-6/S30-201)處理后HeLa細胞遷移和侵襲的變化Fig. 4 Migration and invasion of HeLa treated with SM (serum-free medium), IL-6, IL-6/Ab (IL-6+antibody of IL-6), and IL-6/S30-201 (IL-6+STAT3 inhibitor-S30-201)
本研究用人體宮頸組織中分離的CAFs和NFs進行對比性研究,發(fā)現(xiàn)其分泌的IL-6水平通過激活STAT3信號,提高干細胞轉(zhuǎn)錄因子Snail 1的表達,誘導宮頸癌細胞的EMT發(fā)生和增強細胞遷移和侵襲的能力。
CAFs一般呈衰老狀態(tài),在酸性條件(pH=5.2)下,衰老相關(guān)beta半乳糖苷酶活性上升[12-13]。盡管細胞衰老意味著生命的結(jié)束,但衰老的間質(zhì)細胞由于分泌大量衰老相關(guān)表型,對腫瘤的發(fā)生、發(fā)展卻具有促進作用[13-14]。因此,研究CAFs在腫瘤微環(huán)境中對上皮惡性轉(zhuǎn)化、侵襲和轉(zhuǎn)移具有重要意義。本研究的結(jié)果說明CAFs作為微環(huán)境中IL-6分泌的主要來源,對宮頸癌EMT的發(fā)生起著至關(guān)重要的作用。
IL-6作為炎性細胞因子,與腫瘤血管形成、腫瘤發(fā)生和轉(zhuǎn)移密切相關(guān)[15-16]。其作用機制大多與JAK或STAT3信號通路相關(guān)[15,17]。目前已有人報道IL-6可以誘導乳腺癌細胞CD44表達上升而形成EMT相關(guān)微球體[18]。在頭頸部鱗癌中,內(nèi)皮細胞來源的IL-6也可能誘導癌細胞的EMT發(fā)生[19]。本研究發(fā)現(xiàn)IL-6通過促進STAT3磷酸化,調(diào)節(jié)EMT干細胞標志物Snail 1的表達,同時我們發(fā)現(xiàn)EMT的發(fā)生可增強細胞的遷移和侵襲能力。本試驗的結(jié)果基本證實CAFs通過旁分泌IL-6的方式,誘導宮頸癌EMT發(fā)生和促進腫瘤的遷移和轉(zhuǎn)移,盡管本研究數(shù)據(jù)尚需在動物體內(nèi)和人體宮頸癌標本組織中進行相關(guān)驗證,但這一初步結(jié)論預示著CAFs在腫瘤微環(huán)境中的重要性,因而對宮頸癌轉(zhuǎn)移的診斷、治療和預后可能具有理論價值和臨床意義。
[1]SERVAIS C, EREZ N. From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation [J]. J Pathol, 2013, 229(2): 198-207.
[2]KARAGIANNIS G S, POUTAHIDIS T, ERDMAN S E, et al. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue [J]. Mol Cancer Res, 2012, 10(11): 1403-1418.
[3]ZHANG X H, JIN X, MALLADI S, et al. Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma [J]. Cell, 2013, 154(5): 1060-1073.
[4]CHEN S F, NIEH S, JAO S W, et al. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma [J]. J Pathol, 2013, 231(2): 180-189.
[5]MULHOLLAND D J, KOBAYASHI N, RUSCETTI M, et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/ progenitor cells [J]. Cancer Res, 2012, 72(7): 1878-1889.
[6]BIDDLE A, MACKENZIE I C. Cancer stem cells and EMT in carcinoma [J]. Cancer Metastasis Rev, 2012, [Epub ahead of print].
[7]CIOCE M, CILIBERTO G. On the connections between cancer stem cells and EMT [J]. Cell Cycle, 2012, 11(23): 4301-4302.
[8]OCANA O H, CORCOLES R, FABRA A, et al. Metastatic colonization requires the repression of the epithelialmesenchymal transition inducer Prrx1 [J]. Cancer Cell, 2012, 22(6): 709-724.
[9]TSAI J H, DONAHER J L, MURPHY D A, et al. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis[J]. Cancer Cell, 2012, 22(6): 725-736.
[10]GAO M Q, KIM B G, KANG S, et al. Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro [J]. J Cell Sci, 2010, 123(Pt 20): 3507-3514.
[11]VERED M, DAYAN D, YAHALOM R, et al. Cancerassociated fibroblasts and epithelial-mesenchymal transition in metastatic oral tongue squamous cell carcinoma[J]. Int J Cancer, 2010, 127(6): 1356-1362.
[12]REN C, CHENG X, LU B, et al. Activation of interleukin-6/ signal transducer and activator of transcription 3 by human papillomavirus early proteins 6 induces fibroblast senescence to promote cervical tumourigenesis through autocrine and paracrine pathways in tumour microenvironment [J]. Eur J Cancer, 2013, 49(18): 3889-3899.
[13]KRTOLICA A, PARRINELLO S, LOCKETT S, et al. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging [J]. Proc Natl Acad Sci U S A, 2001, 98(21): 12072-12077.
[14]TCHKONIA T, ZHU Y, VAN DEURSEN J, et al. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities [J]. J Clin Invest, 2013, 123(3): 966-972.
[15]CHANG Q, BOURNAZOU E, SANSONE P, et al. The IL-6/ JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis [J]. Neoplasia, 2013, 15(7): 848-862.
[16]BOTTO S, STREBLOW D N, DEFILIPPIS V, et al. IL-6 in human cytomegalovirus secretome promotes angiogenesis and survival of endothelial cells through the stimulation of survivin[J]. Blood, 2011, 117(1): 352-361.
[17]HATZI E, MURPHY C, ZOEPHEL A, et al. N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth [J]. Oncogene, 2002, 21(22): 3552-3561.
[18]XIE G, YAO Q, LIU Y, et al. IL-6-induced epithelialmesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures[J]. Int J Oncol, 2012, 40(4): 1171-1179.
[19]YADAV A, KUMAR B, DATTA J, et al. IL-6 promotes head and neck tumor metastasis by inducing epithelialmesenchymal transition via the JAK-STAT3-SNAIL signaling pathway [J]. Mol Cancer Res, 2011, 9(12): 1658-1667.
Cancer-associated fibroblasts promotes migration and invasion of cervical epithelial cancer cells through IL-6-induced “epithelial-mesenchymal” transition
REN Chun-xia1, ZHAO Min2, XU Na1, SONG Ya-qin1, CHEN Ya-ping3, LV Bei1, YANG Gong4,5(1.Department of Gynecology and Obstetrics, The People’s Hospital of Wuxi, Wuxi Jiangsu 214023, China; 2.Department of Gynecology and Obstetrics, Shandong Jiaotong Hospital, Jinan Shandong 250031, China; 3.The 5thPeople’s Hospital of Shanghai, Fudan University, Department of Gynecology and Obstetrics, Shanghai Medical College, Fudan University, Shanghai 200240, China; 4.Central Laboratory, The 5thPeople’s Hospital of Shanghai, Fudan University, Department of Gynecology and Obstetrics, Shanghai Medical College, Fudan University, Shanghai 200240, China; 5.Cancer Institute, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China)
LV Bei E-mail: lvbei@wuxiph.com
Background and purpose:Cancer-associated fibroblasts (CAFs) are known to promote theinvasion and metastasis of epithelial cancers. The cytokine IL-6 may mediate the interaction between stromal cells and epithelia in tumor microenvironment to facilitate the invasiveness and metastasis of cancer, however, such mechanism has not been fully covered yet.Methods:We used cervical cancer cell line HeLa as a model for this study. ELISA was used to measure the levels of IL-6 in CAFs and normal fi broblasts (NFs) isolated from squamous cervical cancer or normal cervical tissues. CAFs conditioned medium or IL-6 was used to treat cervical cancer HeLa cell line. The epithelial-mesenchymal transition (EMT) markers such as N-Cadherin and Vimentin were detected by Western blot in cells before and after treatment. Scratches and transwell chambers were used to test the abilities of cell migration and invasion.Results:The levels of IL-6 were 4-5 folds higher in CAFs than in NFs. Treatment of HeLa cells with CAF conditioned medium or IL-6 upregulated N-Cadherin and Vimentin, but down-regulated E-Cadherin and cytokeratin, compared with control cells, indicating that IL-6 may stimulate HeLa cells to EMT. Further study found that Snail 1, the featured transcription factor for stem cells, was increased along with the enhanced phosphorylation of STAT3. Meanwhile, the migration and invasion of HeLa cells treated with IL-6 or CAF conditioned medium were markedly increased.Conclusion:CAF induces the EMT of cervical epithelial cancer cells through IL-6/STAT3/Snail pathway, which thereby promotes the invasiveness and metastasis cervical epithelial cancer.
Cancer-associated fi broblasts; Cervical cancer; Interleukin-6; Epithelial-mesenchymal transition; Migration and invasion
10.3969/j.issn.1007-3969.2014.04.003
R73-37
A
1007-3639(2014)04-0252-06
2013-12-27
2014-03-14)
國家自然科學基金面上項目(No:NSFC91129721)、南京醫(yī)科大學面上基金(No:2012NJMU179)。
呂蓓 E-mail:lvbei@wuxiph.com